Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis

por Yoshino, T., Van Cutsem, E., Li, J., Shen, L., Kim, T.W., Sriuranpong, V., Xuereb, L., Aubel, P., Fougeray, R., Cattan, V., Amellal, N., Ohtsu, A., Mayer, R.J.
Publicado 2022

Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study

por Bordonaro, R., Calvo, A., Auriemma, A., Hollebecque, A., Rubovszky, G., Saunders, M.P., Pápai, Z., Prager, G., Stein, A., André, T., Argilés, G., Cubillo, A., Dahan, L., Edeline, J., Leger, C., Cattan, V., Fougeray, R., Amellal, N., Tabernero, J.
Publicado 2021